Pharma Co. Misled Investors About Hepatitis Drug, Suit Says

Law360, Los Angeles (October 9, 2013, 6:32 PM EDT) -- Biopharmaceutical company Achillion Pharmaceuticals Inc. was hit Wednesday with a proposed class action accusing the company of failing to disclose that its hepatitis drug sovaprevir doesn't interact well with certain other antiviral medications, which ultimately led to a drop in its stock price. 

Joseph Sniezak filed the lawsuit in Connecticut federal court, alleging New Haven, Ct.-based Achillion and some of its executives misrepresented to investors and in financial filings the results of its clinical trials for sovaprevir, maintaining the drug was safe and effective when tests...
To view the full article, register now.




Case Information

Case Title

Sniezak v. Achillion Pharmaceuticals, Inc. et al

Case Number




Nature of Suit



Alvin W. Thompson

Date Filed

October 8, 2013

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.